Finch Therapeutics Group, Inc.
FNCHDelisted Oct 31, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001733257
Finch Therapeutics Group, Inc. was delisted on Oct 31, 2024; its insiders filed their last Form 4 on Jun 10, 2024; no institution reported holding it in 13F filings for Q3 2024; no superinvestor held it.
13F holders, Q1 2024
Institutional positions in Finch Therapeutics Group, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- −6 vs. Q4 2023
- Shares held
- 129.1K
- −80.0K (−38.3%) vs. Q4 2023
- Total value
- $338.2K
- −$416.5K (−55.2%) vs. Q4 2023
- New holders
- 0
- 4 more added
- Sold out
- 6
- 2 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting FNCH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 1 | $29.1K |
| Q1 2024 | 11 | $338.2K |
| Q4 2023 | 17 | $754.7K |
| Q3 2023 | 18 | $1.37M |
| Q2 2023 | 17 | $2.16M |
| Q1 2023 | 33 | $3.75M |
| Q4 2022 | 40 | $4.60M |
| Q3 2022 | 43 | $16.8M |
| Q2 2022 | 47 | $28.0M |
| Q1 2022 | 53 | $53.1M |
| Q4 2021 | 51 | $115.0M |
| Q3 2021 | 45 | $106.8M |
| Q2 2021 | 46 | $77.2M |
| Q1 2021 | 36 | $108.9M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Finch Therapeutics Group, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 27 | $0 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 7 | $18 | 0.00% | +1+16.7% | Added |
| UBS Group AG | 110 | $286 | 0.00% | +108+5,400.0% | Added |
| Morgan Stanley | 156 | $406 | 0.00% | +33+26.8% | Added |
| BlackRock Inc. | 327 | $850 | 0.00% | −14−4.1% | Reduced |
| Bleichroeder LP | 971 | $2.52K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 4,163 | $10.8K | 0.00% | +1,537+58.5% | Added |
| Ikarian Capital, LLC | 6,892 | $18.1K | 0.00% | 00.0% | Unchanged |
| Lake Street Advisors Group, LLC | 21,206 | $55.7K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 36,252 | $94.3K | 0.00% | −2,512−6.5% | Reduced |
| Susquehanna International Group, LLP | 59,028 | $155.2K | 0.00% | 00.0% | Unchanged |
| Baupost Group LLCSuperinvestorBaupost Group | 0 | $0 | 0.00% | −67,296−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −11,746−100.0% | Sold out |
| Northwestern Mutual Wealth Management Co | 0 | $0 | 0.00% | −141−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −12−100.0% | Sold out |
| Moisand Fitzgerald Tamayo, LLC | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Cutler Group LP | 0 | $0 | 0.00% | −3−100.0% | Sold out |